Added to YB: 2024-06-25
Pitch date: 2024-06-21
HROW [bullish]
Harrow, Inc.
+66.34%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States.
Market Cap
$1.3B
Pitch Price
$21.12
Price Target
30.00 (-15%)
Dividend
N/A
EV/EBITDA
29.74
P/E
-253.44
EV/Sales
5.49
Sector
Pharmaceuticals
Category
growth
Show full summary:
Craig-Hallum Raises Harrow Inc. Target Price on Triesence Optimism
$HROW: Craig-Hallum raises PT to $30 from $26, maintains Buy. Triesence relaunch possible Q4'24, adding to 2025 estimates. No 2024 contribution expected; early Q4 launch could provide upside. Triesence progress marks major step toward commercial availability.
Read full article (1 min)